Replies to post #325 on Equity Field Notes from temporal sources

[DanWebzster]

NITE is a clinical stage gene therapy company focusing on currently untreatable retinal diseases.

Commercialization of lead product is 2 - 3 years away.

Lead program is in Ph3. One year follow-up data is expected in 2020.

The second program is Retinitis Pigmentosa. Ph1/2 data will be read out at the 9/18 R&D day. Then, one year follow up data will be due H2/19.

Cash runway extends into 2020. But, there is some possibility of gaining capital thru foreign partnership(s).